Table to HBV reactivation [1.7 vs. 12.0 , pooled OR = 0.19, 95 CI (0.02, 1.84), P = 0.15] (Table three), accompanied by substantial heterogeneity in both incidences of severe hepatitis and extreme hepatitis associated to HBV reactivation, which may be attributed to the study of Long et al. (25) (P = 0.06, Table three) plus the study of Yeo et al. (23) (P = 0.09, Table three), respectively. Sensitive analysis showed that there was fewer incidence of severe hepatitis (P = 0.04, Table 3) and extreme hepatitis associated to HBV reactivation (P = 0.007, Table three) in the prophylactic group in comparison with the control group. Because overt hepatitis was found in moderate hepatitis and extreme hepatitis clinically, combination evaluation of incidences of moderate and serious hepatitis, in parallel to mixture analysis of incidences of moderate and serious hepatitis related to HBV reactivation was performed. Both with the combined incidences of moderate and extreme hepatitis [7.6 vs. 31.7 , pooled OR = 0.20, 95 CI (0.07, 0.58), P = 0.003] (TableNMNMPYeo et al. (2004) 36 19 CNMNMPLong et al. (2011) three six CPYun et al. (2011) 25 16 C3) along with the combined incidences of moderate and extreme hepatitis attributable to HBV reactivation [2.5 vs. 17.four ,Table three. MetaAnalysis on the Various Outcomes Trials P C Chi2, P value; I2 0.97, 0.81; 0 ten.03, 0.02; 70 0.57, 0.75; 0 4.04, 0.26; 26 3.32, 0.35; 10 7.26, 0.06; 59 four.59, 0.20; 35Zheng Y et al.Lamivudine and breast cancer individuals with HBsAg optimistic pooled OR = 0.16, 95 CI (0.05, 0.51), P = 0.002] (Table 3)Participants 167 167 167 167 167 167Pooled OR, (95 CI), P value 0.09, (0.03, 0.26), 0.0001 0.23, (0.06, 0.92), 0.04 0.10, (0.03, 0.32), 0.HBV Reactivation Hepatitis Hepatitis Attributable to HBV Reactivation Severity of hepatitis Mild Moderate Severe Moderate and Severe4 4 4 four 4 4118 118 118 118 118 118Pooled OR, (95 CI), P worth; Trials Omitted 0.Buy844501-00-4 ten, (0.175281-76-2 Data Sheet 03, 0.32), 0.0001; Dai et al. 0.12, (0.03, 0.39), 0.0006; Dai et al. 0.76, (0.18, three.24), 0.71; Dai et al. 0.14, (0.07, 0.29), 0.00001; Extended et al.Sensitive Analysis0.90, (0.27, three.03), 0.87 0.36, (0.11, 1.26), 0.11 0.27, (0.04, 1.88), 0.0.25, (0.07, 0.90), 0.03; Dai et al. 0.23, (0.05, 0.99), 0.05; Dai et al.Severity of Hepatitis Attributable to HBV Reactivation Mild Moderate Extreme Moderate and Severe0.20, (0.07, 0.58), 0.003 0.16, (0.02, 1.30), 0.09 0.19, (0.02, 1.84), 0.15 0.42, (0.11, 1.58), 0.0.14, (0.02, 0.87), 0.04; Extended et al.four 4 4 four 3 3 3118 118 118 118 107 107 87167 167 167 167 158 158 1060.22, 0.64; 0 1.62, 0.45; 0 1.62, 0.45; 0 4.76, 0.09; 58 four.94, 0.08; 59 0.05, 0.83; 00.36, (0.07, two.03), 0.25 0.16, (0.05, 0.51), 0.002 0.11, (0.02, 0.58), 0.0.16, (0.02, 1.30), 0.09; Dai et al. 0.41, (0.03, 5.18), 0.49; Dai et al. 0.06, (0.PMID:33593152 01, 0.46), 0.007; Yeo et al. 0.19, (0.05, 0.69), 0.01; Dai et al. 0.23, (0.09, 0.55), 0.001; Lengthy et al. 0.11, (0.02, 0.58), 0.01; Extended et al. 0.38, (0.04, 3.76), 0.41; Dai et al. Not performedChemotherapy Disruption Chemotherapy Disruption Attributable to HBV Reactivation General Mortality0.03, 0.99; 0 Not availableMortality Attributable to HBV Reactivation0.37, (0.07, two.04), 0.25 0.25, (0.01, 6.82), 0.were lower inside the prophylactic lamivudine group than within the manage group. There was no significant heterogeneity in both two combined incidences (Table three). Sensitive evaluation showed that the distinction was still statistically considerable within the combined incidences of moderate and serious hepatitis related to HBV reactivation (P = 0.01, Table.